HT-2157

From Wikipedia, the free encyclopedia
(Redirected from SNAP-37889)
HT-2157
Structural formula
Space-filling model
Clinical data
ATC code
  • none
Identifiers
  • 1-Phenyl-3-[3-(trifluoromethyl)phenyl]iminoindol-2-one
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
FormulaC21H13F3N2O
Molar mass366.343 g·mol−1
3D model (JSmol)
  • c14ccccc4n(-c3ccccc3)c(=O)c1=N\c(c2)cccc2C(F)(F)F
  • InChI=1S/C21H13F3N2O/c22-21(23,24)14-7-6-8-15(13-14)25-19-17-11-4-5-12-18(17)26(20(19)27)16-9-2-1-3-10-16/h1-13H/b25-19+
  • Key:TXCGMRVPXUBHAL-NCELDCMTSA-N

HT-2157 (former development code SNAP-37889) is a drug which acts as a selective non-peptide antagonist for the receptor GAL-3, which is usually activated by the neuropeptide galanin. Blocking this receptor with HT-2157 produced increased serotonin release,[1] as well as producing antidepressant and anxiolytic effects in animal studies,[2] and it was also being researched for treatment of cognitive dysfunction.[3] All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.[4]

References[edit]

  1. ^ "pA2 Online". www.pa2online.org.
  2. ^ Swanson CJ, Blackburn TP, Zhang X, Zheng K, Xu ZQ, Hökfelt T, et al. (November 2005). "Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299". Proceedings of the National Academy of Sciences of the United States of America. 102 (48): 17489–94. doi:10.1073/pnas.0508970102. PMC 1283534. PMID 16287967.
  3. ^ US 8277842, Kaplan AP, "Enteric-coated HT-2157 compositions and methods of their use", published January 20, 2012 
  4. ^ "Dart NeuroScience LLC -- Scientific Advisory Board". www.dartneuroscience.com.